Jon Genuneit

Jon Genuneit

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 February 2011 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
MEMe Ee
Me Ee
MMMelanie Mayer
Melanie Mayer
ANAnne-Cécile Normand
Anne-Cécile Normand
JGJon Genuneit
Jon Genuneit
WCWilliam O.C.M. Cookson
William O.C.M. Cookson
EMErika von Mutius
Erika von Mutius
Children who grow up in environments that afford them a wide range of microbial exposures, such as traditional farms, are protected from childhood asthma and atopy. In previous studies, markers of microbial exposure have been inversely related to these conditions.

22 December 2017 in Nature Genetics
Verified
Journal Article
Open access
PDF file
FDFlorence Demenais
Florence Demenais
PMPatricia Margaritte-Jeannin
Patricia Margaritte-Jeannin
KBKathleen C Barnes
Kathleen C Barnes
WCWilliam Oc Cookson
William Oc Cookson
JAJanine Altmüller
Janine Altmüller
DNDan Nicolae
Dan Nicolae
We examined common variation in asthma risk by conducting a meta-analysis of worldwide asthma genome-wide association studies (23,948 asthma cases, 118,538 controls) of individuals from ethnically diverse populations. We identified five new asthma loci, found two new associations at two known asthma loci, established asthma associations at two loci previously implicated in the comorbidity of asthma plus hay fever, and confirmed nine known loci. Investigation of pleiotropy showed large overlaps in genetic variants with autoimmune and inflammatory diseases. The enrichment in enhancer marks at asthma risk loci, especially in immune cells, suggested a major role of these loci in the regulation of immunologically related mechanisms.

1 July 2021 in European Respiratory Journal
Verified
Journal Article
Open access
PDF file
IOIsmail M. Osmanov
Ismail M. Osmanov
ESEkaterina Spiridonova
Ekaterina Spiridonova
PBPolina Bobkova
Polina Bobkova
AGAysylu Gamirova
Aysylu Gamirova
ASAnastasia Shikhaleva
Anastasia Shikhaleva
DMDaniel Munblit
Daniel Munblit
Background: The long-term sequelae of coronavirus disease 2019 (COVID-19) in children remain poorly characterised. This study aimed to assess long-term outcomes in children previously hospitalised with COVID-19 and associated risk factors.Methods: This is a prospective cohort study of children (≤18 years old) admitted to hospital with confirmed COVID-19. Children admitted between 2 April 2020 and 26 August 2020 were included. Telephone interviews used the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) COVID-19 Health and Wellbeing Follow-up Survey for Children. Persistent symptoms (>5 months) were further categorised by system(s) involved.Results: 518 out of 853 (61%) eligible children were available for the follow-up assessment and included in the study. Median (interquartile range (IQR)) age was 10.4 (3–15.2) years and 270 (52.1%) were girls. Median (IQR) follow-up since hospital discharge was 256 (223–271) days. At the time of the follow-up interview 126 (24.3%) participants reported persistent symptoms, among which fatigue (53, 10.7%), sleep disturbance (36, 6.9%) and sensory problems (29, 5.6%) were the most common. Multiple symptoms were experienced by 44 (8.4%) participants. Risk factors for persistent symptoms were: older age “6–11 years” (OR 2.74, 95% CI 1.37–5.75) and “12–18 years” (OR 2.68, 95% CI 1.41–5.4), and a history of allergic diseases (OR 1.67, 95% CI 1.04–2.67).Conclusions: A quarter of children experienced persistent symptoms months after hospitalisation with acute COVID-19 infection, with almost one in 10 experiencing multisystem involvement. Older age and allergic diseases were associated with higher risk of persistent symptoms at follow-up.

1 July 2017 in JAMA Pediatrics
Verified
Journal Article
Open access
PDF file
CRCaroline Roduit
Caroline Roduit
RFRemo Frei
Remo Frei
MDMartin Depner
Martin Depner
AKAnne M. Karvonen
Anne M. Karvonen
HRHarald Renz
Harald Renz
GDGert Doekes
Gert Doekes
More than 20% of children in industrialized countries have atopic dermatitis.1-4 In more than 60% of these children, the disease started within the first 2 years of life.5 Even though many children will outgrow the disease, in others it will persist.6 Atopic dermatitis is considered to be one of the first manifestations in the atopic march, which describes the typical progression of clinical symptoms of allergic diseases during childhood. Several studies have shown that atopic dermatitis is positively associated with asthma.7-9 The risk of developing asthma among children with atopic dermatitis was shown to be increased by 2 compared with children with no atopic dermatitis.10

1 April 2014 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
CRCaroline Roduit
Caroline Roduit
RFRemo Frei
Remo Frei
MDMartin Depner
Martin Depner
BSBianca Schaub
Bianca Schaub
GLGeorg Loss
Georg Loss
RLRoger Lauener
Roger Lauener

1 October 2011 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
GLGeorg Loss
Georg Loss
SASilvia Apprich
Silvia Apprich
MWMarco Waser
Marco Waser
WKWolfgang Kneifel
Wolfgang Kneifel
JGJon Genuneit
Jon Genuneit
CBCharlotte Braun-Fahrländer
Charlotte Braun-Fahrländer